Janus Biotherapeutics is developing a novel, orally available TLR 7/8/9 receptor antagonist for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome and psoriasis.  There is widespread scientific consensus that TLRs or Toll-like receptors play an important role in the immune system and in aberrant immune responses.   By blocking these unwanted immune responses, a TLR 7/8/9 antagonist offers the promise of providing a novel therapy for a wide range of autoimmune diseases.

Learn more: http://www.janusbio.com/